Initial Results of Robotic Surgery for Primary Lung Cancer : Feasibility, Safety and Learning Curve

• Published in: YONAGO ACTA MEDICA Vol. 60; no. 3; pp. 162 - 166
• Main Authors: Taniguchi, Yuji, Nakamura, Hiroshige, Miwa, Ken, Haruki, Tomohiro, Araki, Kunio, Takagi, Yuzo, Wakahara, Makoto, Yurugi, Yohei, Kubouchi, Yasuaki, Ohno, Takashi, Kidokoro, Yoshiteru, Fujiwara, Wakako
• Format: Journal Article
• Language: English
• Published: Japan Tottori University Faculty of Medicine 01.09.2017
• Subjects: Original; primary lung cancer; initial results; robotic surgery
• DOI: 10.33160/yam.2017.09.004
• ISSN: 0513-5710

[ABSTRACT] [Background] At the end of 2016, robot-assisted thoracoscopic surgery (RATS) was still not covered by Japanese national health insurance. Therefore, few institutions in Japan perform RATS and even fewer have reported procedures as they occurred earlier. So, we decided to focus on the initial results of RATS for primary lung cancer. [Methods] We retrospectively reviewed 44 patients who underwent RATS for primary lung cancer from January 2011 to August 2016. After mastering the initial procedure, we introduced a completely portal robotic pulmonary resection procedure using a carbon dioxide insufflation system. Cases were divided into 2 groups: the early period (20 cases) and the later period (24 cases). [Results] There was no case of conversion to video-assisted thoracoscopic surgery or thoracotomy. In the 44 cases of primary lung cancer, median operating time was 239.5 min, console time was 179 min, blood loss was 10 mL, drainage period was 2 days, morbidity of Grade 2 or more (Clavien-Dindo classification) was 18.2%, morbidity of Grade 3 or more was only 4.6%, and there was no 30-day mortality. Median operating and console times were significantly shorter in the later period (215 min and 159.5 min, respectively) than in the initial period (300.5 min and 228 min, respectively). Median blood loss was significantly lower in the later period (5 mL) than in the initial period (50 mL). Fiveyear overall and disease-free survival rates were 100% and 88.9%, respectively. [Conclusion] RATS for primary lung cancer is feasible and safe, has a faster learning curve, and provides satisfactory. Studies with longer follow-ups and larger numbers of cases are necessary.